Double-blind cross-over study of indoprofen versus ibuprofen and placebo in rheumatoid arthritis patients.

Thirty patients with classical or definite rheumatoid arthritis were given indoprofen 800 mg/day, ibuprofen 1200 mg/day or placebo in a double-blind cross-over trial, for three consecutive 10-day periods. The two drugs were both superior to placeto, intoprofen on more parameters than ibuprofen. Indoprofen was on the whole better than ibuprofen and the difference was statistically significant on pain, grip strength, morning stiffness, patients' preference and investigators' opinion of the therapeutic effect. Both drugs were well tolerated clinically.